Recently, the benefit of combining the anti-HER2 antibody trastuzumab with chemotherapy in reducing the rate of recurrence mortality of resected, HER2 overexpressing breast cancer was established [2]. The gene discussed is ERBB2; the disease is breast carcinoma.